Updates are available Correction dated 2022-05-18
Click to view Correction: https://doi.org/10.1186/s13023-022-02363-0
-
Authors
Banerjee, Indraneel https://orcid.org/0000-0003-4280-7470
Raskin, Julie
Arnoux, Jean-Baptiste
De Leon, Diva D.
Weinzimer, Stuart A.
Hammer, Mette
Kendall, David M.
Thornton, Paul S.
-
Funding
Funding for this research was provided by:
Zealand Pharma A/S
- License Information
-
More Information
Article History
Received: 13 September 2021
Accepted: 6 February 2022
First Online: 19 February 2022
Change Date: 18 May 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13023-022-02363-0
Declarations
:
: Not applicable.
: Not applicable.
: IB has been involved (independently of this work) in research contracts with Crinetics Pharmaceuticals, Dexcom Incorporated, Merck Serono and Zealand Pharma. He has received fees for advisory board meetings with Merck Serono. He has national commitments as Chair of the British Society of Paediatric Endocrinology and Diabetes Clinical Study Group, Audit and Peer Review Officer of the BSPED, Chair of the European Society for Paediatric Endocrinology, and co-opted member of the Head Injury Guidelines Committee for the National Institute of Health and Care Excellence in the UK. JR is an employee of CHI International, who have received sponsorship for events from Amidebio, Betabionics, Crinetics Pharmaceuticals, Eiger, Hanmi, Rezolute, Twist and Zealand Pharma over the past 3 years. Crinetics Pharmaceuticals, Eiger, Hanmi Pharmaceuticals, Rezolute and Zealand Pharma are current sponsors of the HI Global Registry. JR does not receive any fees directly from the companies. J-BA received consulting fees (independent of this work) from Alexion, BioMarin, Immedica, Lucane Pharma and Zealand Pharma, and speaker fees from Pierre Fabre and Sanofi Genzyme. DDDL received consulting fees (independent of this work) from Crinetics Pharmaceuticals, Hanmi Pharmaceuticals, Heptares Therapeutics, Poxel Inc., Soleno Therapeutics and Zealand Pharma, and research support from Crinetics Pharmaceuticals, Tiburio Pharma, Twist Pharma and Zealand Pharma. DDDL owns stock options from Merck & Co through spouse employment. SAW received speaker fees (independent of this work) from Abbott, Dexcom and Medtronic, and serves as a consultant for Zealand Pharma A/S. MH and DMK are full-time employees and shareholders of Zealand Pharma A/S, Soborg, Denmark. PST received payments (independent of this work) from Ascendis, Novo Nordisk, Opko Biologics, Rezolute, Spruce, Xeris Pharmaceuticals and Zealand Pharma for performing research studies, and payments from Johnson and Johnson and Nutricia for expert testimony.
